PARTNERSHIPS AND COMMERCIAL AGREEMENTS
VIVUS collaborates with Menapharm and PharmaAccess, its commercial partners in the Middle East & North Africa (MENA) region to provide access to the medication.
LIMITATIONS OF USE
The effect of QSYMIA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSYMIA in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
WARNINGS AND PRECAUTIONS
QSYMIA (phentermine and topiramate extended-release capsules) is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSYMIA.
QSYMIA can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during QSYMIA therapy. If a patient becomes pregnant while taking QSYMIA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.
United Arab Emirates
Bahrain